Despite several studies indicating that women with copper IUDs suffer from worse dysmenorrhea than those who don’t have the device, a recent study published on April 11, 2013, in Human Reproduction indicates that this may not be entirely accurate.
Despite several studies indicating that women with copper IUDs suffer from worse dysmenorrhea than those who don’t have the device, a recent study published on April 11, 2013, in Human Reproduction indicates that this may not be entirely accurate.
Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, studied 2,100 women over a 30-year period. Nineteen-year-old women born in 1962 (n =656), 1972 (n = 780), and 1982 (n = 666) were randomly chosen and assessed every 5 years between 1981 and 2001. Each woman was asked about her pregnancies, children, height, weight, and contraception. Women who indicated that they suffered from dysmenorrhea had the severity assessed by verbal multidimensional scoring system (VMS) and a visual analog scale (VAS).
The results indicated that the pain severity was the same for women using copper IUDs as women who used no form of contraception or other forms of contraception such as condom and barrier methods (VMS score: +0.05 units/VAS: =0.3mm, both NS). However, women who used levonorgestrel-releasing intrauterine systems (LNG-IUS) or combined oral contraceptives (COC) were shown to have less severe dysmenorrhea (LNG-IUS use, VMS score: -0.4 units/VAS: -13 mm, both P <0.01; COC use, VMS score: -0.4 units/VAS: -11 mm, both P <0.0001). Investigators also found that women who had given birth had less severe dysmenorrhea as well (VMS score: -0.3 units, P <0.05/ VAS: -16 mm, P <0.001). The women in the study also indicated that the severity decreased between ages 19 and 44.
While the study indicates that copper IUDs have no influence on dysmenorrhea severity, the researchers cautioned that the response rate did decline over the study period. Women were also not asked about endometriosis or adenomyosis, both of which can be confounding factors for dysmenorrhea.
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Treating heavy menstrual bleeding: Levonorgestrel system vs combined oral contraceptives
November 8th 2023In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.
Read More
Enhancing contraceptive use among female smokers
October 26th 2023Women of reproductive age often use combined hormonal contraceptives, which are available orally, as a vaginal ring, or as a transdermal patch. However, CHCs are associated with increased risks of venous thromboembolism and myocardial infarction (MI).
Read More